Randomized, controlled clinical trial for low-dose interleukin-2 in the treatment of moderate to severe bullous pemphigoid

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000028707

Enrollment

Unknown

Registered

2020-01-01

Start date

2020-01-01

Completion date

Unknown

Last updated

2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bullous pemphigoid

Interventions

Moderate BP group 1:Standard treatment plan

Moderate BP group 2:low dose interleukin-2

Severe BP group 1:Standard treatment plan

Severe BP group 2:low dose interleukin-2

Eligibility

Sex/Gender

All

Age

12 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Aged >=12 year male and female; 2. Patients with bullous pemphigoid have been diagnosed; 3. BPDAI score >30; 4. Stable vital signs; 5. The subjects have signed the informed consent and are able to follow the clinical research plan.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Any disease that interferes with the evaluation of test results, such as abnormal immune function, abnormal renal and liver function, serious cardiovascular disease, malignant tumor, acute and chronic infection, etc; 3. Blood glucose or blood pressure are not effectively controlled; 4. Antibiotics,glucocorticoids and immunosuppressants were used systematically in the past one month; 5. Accompanied by psychosis or unable to cooperate in the treatment.

Design outcomes

Primary

Measure	Time frame
BPDAI;Treg cells in peripheral blood;BP180;BP230;	—

Secondary

Measure	Time frame
Pruritus score;	—

Countries

China

Contacts

Public ContactXUE RUZENG

Dermatology Hospital, Southern Medical University

xueruzeng@163.com+86 13632405126

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026